Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome
Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high lev...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2000-09, Vol.24 (9), p.777-789 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 789 |
|---|---|
| container_issue | 9 |
| container_start_page | 777 |
| container_title | Leukemia research |
| container_volume | 24 |
| creator | Li, Biarou Yang, Jie Tao, Ming Nayini, Jaya Horvath, Erzsebet Chopra, Harpareet Meyer, PeterM Venugopal, Paramesaran Preisler, Harvey D |
| description | Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. |
| doi_str_mv | 10.1016/S0145-2126(00)00035-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72248860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212600000357</els_id><sourcerecordid>72248860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-293fe5b680551cf88f28e16e837012cc2b8f9dc702d97d84af953673bcdb2dd53</originalsourceid><addsrcrecordid>eNqFkMtu1TAQhi0EoqeFRwB5gVBZBHw5jp1VhSoulSoVCVhbznhSDElcbAfp7HgInrBPgs9FpTtWs5jvn8tHyDPOXnPG2zefGV-rRnDRnjL2ijEmVaMfkBU3WjbKSPWQrO6QI3Kc8_cKqY53j8kRZ5022sgV2XyKMdGbFK_nmEOmDpaCdNrgGK9xjkumIy4_cAqOCnr7-w_tQ6ytAG6kbvZ0iiPCMrp0vwHfXHJQMIVcAuQdWBK6MuFcaFwKxAmfkEeDGzM-PdQT8vX9uy_nH5vLqw8X528vG5AdK43o5ICqbw1TisNgzCAM8haN1IwLANGbofOgmfCd9mbthk7JVssefC-8V_KEvNzPrU_-XDAXO4UMOI5uxvqf1UKsjWlZBdUehBRzTjjYmxQmlzaWM7t1bnfO7VaoZczunFtdc88PC5Z-Qn8vtZdcgRcHwOWqZ0huhpD_cWttBNseerbHsNr4FTDZDAFnQB8SQrE-hv9c8hcJ1qDh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72248860</pqid></control><display><type>article</type><title>Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Li, Biarou ; Yang, Jie ; Tao, Ming ; Nayini, Jaya ; Horvath, Erzsebet ; Chopra, Harpareet ; Meyer, PeterM ; Venugopal, Paramesaran ; Preisler, Harvey D</creator><creatorcontrib>Li, Biarou ; Yang, Jie ; Tao, Ming ; Nayini, Jaya ; Horvath, Erzsebet ; Chopra, Harpareet ; Meyer, PeterM ; Venugopal, Paramesaran ; Preisler, Harvey D</creatorcontrib><description>Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/S0145-2126(00)00035-7</identifier><identifier>PMID: 10978783</identifier><identifier>CODEN: LEREDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Amifostine ; Amifostine - therapeutic use ; AML ; Antineoplastic agents ; Base Sequence ; Biological and medical sciences ; Chemotherapy ; Cytokines ; DNA Primers ; Humans ; Leukemia, Myeloid, Acute - pathology ; Medical sciences ; Pharmacology. Drug treatments ; Prognosis ; Remission induction ; Treatment Outcome</subject><ispartof>Leukemia research, 2000-09, Vol.24 (9), p.777-789</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-293fe5b680551cf88f28e16e837012cc2b8f9dc702d97d84af953673bcdb2dd53</citedby><cites>FETCH-LOGICAL-c390t-293fe5b680551cf88f28e16e837012cc2b8f9dc702d97d84af953673bcdb2dd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0145-2126(00)00035-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1478205$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10978783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Biarou</creatorcontrib><creatorcontrib>Yang, Jie</creatorcontrib><creatorcontrib>Tao, Ming</creatorcontrib><creatorcontrib>Nayini, Jaya</creatorcontrib><creatorcontrib>Horvath, Erzsebet</creatorcontrib><creatorcontrib>Chopra, Harpareet</creatorcontrib><creatorcontrib>Meyer, PeterM</creatorcontrib><creatorcontrib>Venugopal, Paramesaran</creatorcontrib><creatorcontrib>Preisler, Harvey D</creatorcontrib><title>Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow.</description><subject>Amifostine</subject><subject>Amifostine - therapeutic use</subject><subject>AML</subject><subject>Antineoplastic agents</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cytokines</subject><subject>DNA Primers</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Remission induction</subject><subject>Treatment Outcome</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtu1TAQhi0EoqeFRwB5gVBZBHw5jp1VhSoulSoVCVhbznhSDElcbAfp7HgInrBPgs9FpTtWs5jvn8tHyDPOXnPG2zefGV-rRnDRnjL2ijEmVaMfkBU3WjbKSPWQrO6QI3Kc8_cKqY53j8kRZ5022sgV2XyKMdGbFK_nmEOmDpaCdNrgGK9xjkumIy4_cAqOCnr7-w_tQ6ytAG6kbvZ0iiPCMrp0vwHfXHJQMIVcAuQdWBK6MuFcaFwKxAmfkEeDGzM-PdQT8vX9uy_nH5vLqw8X528vG5AdK43o5ICqbw1TisNgzCAM8haN1IwLANGbofOgmfCd9mbthk7JVssefC-8V_KEvNzPrU_-XDAXO4UMOI5uxvqf1UKsjWlZBdUehBRzTjjYmxQmlzaWM7t1bnfO7VaoZczunFtdc88PC5Z-Qn8vtZdcgRcHwOWqZ0huhpD_cWttBNseerbHsNr4FTDZDAFnQB8SQrE-hv9c8hcJ1qDh</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Li, Biarou</creator><creator>Yang, Jie</creator><creator>Tao, Ming</creator><creator>Nayini, Jaya</creator><creator>Horvath, Erzsebet</creator><creator>Chopra, Harpareet</creator><creator>Meyer, PeterM</creator><creator>Venugopal, Paramesaran</creator><creator>Preisler, Harvey D</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome</title><author>Li, Biarou ; Yang, Jie ; Tao, Ming ; Nayini, Jaya ; Horvath, Erzsebet ; Chopra, Harpareet ; Meyer, PeterM ; Venugopal, Paramesaran ; Preisler, Harvey D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-293fe5b680551cf88f28e16e837012cc2b8f9dc702d97d84af953673bcdb2dd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amifostine</topic><topic>Amifostine - therapeutic use</topic><topic>AML</topic><topic>Antineoplastic agents</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cytokines</topic><topic>DNA Primers</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Remission induction</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Biarou</creatorcontrib><creatorcontrib>Yang, Jie</creatorcontrib><creatorcontrib>Tao, Ming</creatorcontrib><creatorcontrib>Nayini, Jaya</creatorcontrib><creatorcontrib>Horvath, Erzsebet</creatorcontrib><creatorcontrib>Chopra, Harpareet</creatorcontrib><creatorcontrib>Meyer, PeterM</creatorcontrib><creatorcontrib>Venugopal, Paramesaran</creatorcontrib><creatorcontrib>Preisler, Harvey D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Biarou</au><au>Yang, Jie</au><au>Tao, Ming</au><au>Nayini, Jaya</au><au>Horvath, Erzsebet</au><au>Chopra, Harpareet</au><au>Meyer, PeterM</au><au>Venugopal, Paramesaran</au><au>Preisler, Harvey D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>24</volume><issue>9</issue><spage>777</spage><epage>789</epage><pages>777-789</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><coden>LEREDD</coden><abstract>Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10978783</pmid><doi>10.1016/S0145-2126(00)00035-7</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2000-09, Vol.24 (9), p.777-789 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72248860 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Amifostine Amifostine - therapeutic use AML Antineoplastic agents Base Sequence Biological and medical sciences Chemotherapy Cytokines DNA Primers Humans Leukemia, Myeloid, Acute - pathology Medical sciences Pharmacology. Drug treatments Prognosis Remission induction Treatment Outcome |
| title | Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A59%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poor%20prognosis%20acute%20myelogenous%20leukemia%202%20%E2%80%94%20biological%20and%20molecular%20biological%20characteristics%20and%20treatment%20outcome&rft.jtitle=Leukemia%20research&rft.au=Li,%20Biarou&rft.date=2000-09-01&rft.volume=24&rft.issue=9&rft.spage=777&rft.epage=789&rft.pages=777-789&rft.issn=0145-2126&rft.eissn=1873-5835&rft.coden=LEREDD&rft_id=info:doi/10.1016/S0145-2126(00)00035-7&rft_dat=%3Cproquest_cross%3E72248860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72248860&rft_id=info:pmid/10978783&rft_els_id=S0145212600000357&rfr_iscdi=true |